| Product NDC: | 63323-105 |
| Proprietary Name: | Acyclovir |
| Non Proprietary Name: | ACYCLOVIR SODIUM |
| Active Ingredient(s): | 50 mg/mL & nbsp; ACYCLOVIR SODIUM |
| Administration Route(s): | INTRAVENOUS |
| Dosage Form(s): | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 63323-105 |
| Labeler Name: | APP Pharmaceuticals, LLC |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA075015 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20001017 |
| Package NDC: | 63323-105-10 |
| Package Description: | 10 VIAL in 1 TRAY (63323-105-10) > 10 mL in 1 VIAL |
| NDC Code | 63323-105-10 |
| Proprietary Name | Acyclovir |
| Package Description | 10 VIAL in 1 TRAY (63323-105-10) > 10 mL in 1 VIAL |
| Product NDC | 63323-105 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | ACYCLOVIR SODIUM |
| Dosage Form Name | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
| Route Name | INTRAVENOUS |
| Start Marketing Date | 20001017 |
| Marketing Category Name | ANDA |
| Labeler Name | APP Pharmaceuticals, LLC |
| Substance Name | ACYCLOVIR SODIUM |
| Strength Number | 50 |
| Strength Unit | mg/mL |
| Pharmaceutical Classes | DNA Polymerase Inhibitors [MoA],Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC],Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC],Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient] |